Elizabeth Plimack, MD, MS

Elizabeth Plimack, MD, MS, director of Genitourinary Unirnary Research, Fox Chase Cancer Center, discusses the monoclonal antibody ipilimumab and its uncertain efficacy in bladder cancer. Plimack says the efficacy of PD-L1 inhibitors have been proven in the treatment of bladder cancer and are currently employed in the armamentarium of medical professionals. She adds as other cancer types further test both ipilimumab and PD-L1 inhibitors, oncologists will gain a better understanding of how both will continue to play a role in bladder cancer.

Plimack says data presented over the course of the past year will also aid oncologists in potentially utilizing combinations of ipilimumab and chemoimmunotherapies.

Videos

Plimack says the efficacy of PD-L1 inhibitors have been proven in the treatment of bladder cancer and are currently employed in the armamentarium of medical professionals. She adds as other cancer types further test both ipilimumab and PD-L1 inhibitors, oncologists will gain a better understanding of how both will continue to play a role in bladder cancer.

Dr. Elizabeth Plimack on Ipilimumab and PD-L1 Inhibitors in the Treatment of Bladder Cancer

Elizabeth Plimack, MD, MS, attending physician, genitourinary cancer associate professor, Medical Oncology Director of Genitourinary Clinical Research, Fox Chase Cancer Center, discusses a study that examined pembrolizumab in patients with urothelial cancer.

Pembrolizumab in Urothelial Cancer

Elizabeth Plimack, MD, MS, director, Genitourinary Clinical Research, Fox Chase Cancer Center, discusses a phase Ib study of pembrolizumab for the treatment of patients with bladder cancer.

33 patients with urothelial tract cancer were enrolled on this trial.

A subset of patients experienced a decrease in tumor volume. There were 3 complete responses.

Overall survival data seen in this study were at the top bound of historical data.

Articles

A Phase Ib Study of Pembrolizumab in Bladder Cancer

Elizabeth Plimack, MD, MS, attending physician, medical oncology, Fox Chase Cancer Center, discusses a phase I trial looking at overcoming mTOR resistance in renal cell carcinoma (RCC).

This study represents the first step in a long process: testing the hypothesis that HDAC inhibition can overcome resistance to mTOR inhibition

Two patients treated with prior mTOR inhibitors progressed and then did well when treated with the combination of ridaforolimus and vorinostat

Ridaforolimus 20 mg once daily plus vorinostat 100 mg once daily will be tested in a larger trial in patients who had both prior mTOR inhibitors and those who did not

Elizabeth Plimack, MD, MS | Authors

Articles

Dr. Elizabeth Plimack on Ipilimumab and PD-L1 Inhibitors in the Treatment of Bladder Cancer

Pembrolizumab in Urothelial Cancer

A Phase Ib Study of Pembrolizumab in Bladder Cancer

Overcoming mTOR Resistance in Renal Cell Carcinoma